Resistance to breast cancer drugSCO-101
Project summary
The new-still premature drug, working title SCO-101, is intended to ensure that breast cancer tumor cells are no longer resistant to the drug used to treat them. This resistance occurs in a significant proportion of breast cancer patients treated with tamoxifen. This is a drug that is prescribed as a follow-up treatment to prevent any metastases from growing into new tumors.
Impact
For all currently known genes that cause the tumor cell to become resistant to tamoxifen, he will investigate whether SCO-101 is able to reverse the resistance. And if so, try to clarify through which mechanism SCO-101 accomplishes this.
More detailed information
Principal Investigator:
John Martens
Role Erasmus MC:
Coördinator
Department:
Department
Project website:
Not available
Funding Agency:
Funding Agency